These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 34061123)
1. Cushing Disease with Glucocorticoid-induced Positive Feedback-A New Subtype of Pituitary Corticotropinomas? Tóth M J Endocr Soc; 2021 Jun; 5(6):bvab079. PubMed ID: 34061123 [No Abstract] [Full Text] [Related]
2. PATHOGENESIS OF CUSHING DISEASE: AN UPDATE ON THE GENETICS OF CORTICOTROPINOMAS. Albani A; Perez-Rivas LG; Reincke M; Theodoropoulou M Endocr Pract; 2018 Oct; 24(10):907-914. PubMed ID: 30084690 [TBL] [Abstract][Full Text] [Related]
3. ACTH-Dependent Cyclic Cushing Syndrome Triggered by Glucocorticoid Excess Through a Positive-Feedback Mechanism. Seki Y; Morimoto S; Saito F; Takano N; Kimura S; Yamashita K; Yoshida N; Bokuda K; Sasaki N; Yatabe M; Watanabe D; Yatabe J; Ando T; Amano K; Kawamata T; Ichihara A J Clin Endocrinol Metab; 2019 May; 104(5):1788-1791. PubMed ID: 30561712 [TBL] [Abstract][Full Text] [Related]
4. A cellular and molecular basis for the selective desmopressin-induced ACTH release in Cushing disease patients: key role of AVPR1b receptor and potential therapeutic implications. Luque RM; Ibáñez-Costa A; López-Sánchez LM; Jiménez-Reina L; Venegas-Moreno E; Gálvez MA; Villa-Osaba A; Madrazo-Atutxa AM; Japón MA; de la Riva A; Cano DA; Benito-López P; Soto-Moreno A; Gahete MD; Leal-Cerro A; Castaño JP J Clin Endocrinol Metab; 2013 Oct; 98(10):4160-9. PubMed ID: 23884782 [TBL] [Abstract][Full Text] [Related]
5. Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus. Huizenga NA; de Lange P; Koper JW; Clayton RN; Farrell WE; van der Lely AJ; Brinkmann AO; de Jong FH; Lamberts SW J Clin Endocrinol Metab; 1998 Mar; 83(3):917-21. PubMed ID: 9506748 [TBL] [Abstract][Full Text] [Related]
6. Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumors. Korbonits M; Bujalska I; Shimojo M; Nobes J; Jordan S; Grossman AB; Stewart PM J Clin Endocrinol Metab; 2001 Jun; 86(6):2728-33. PubMed ID: 11397878 [TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanisms of Glucocorticoid Resistance in Corticotropinomas: New Developments and Drug Targets. Ciato D; Albani A Front Endocrinol (Lausanne); 2020; 11():21. PubMed ID: 32117053 [TBL] [Abstract][Full Text] [Related]
10. Large Genomic Aberrations in Corticotropinomas Are Associated With Greater Aggressiveness. Tatsi C; Pankratz N; Lane J; Faucz FR; Hernández-Ramírez LC; Keil M; Trivellin G; Chittiboina P; Mills JL; Stratakis CA; Lodish MB J Clin Endocrinol Metab; 2019 May; 104(5):1792-1801. PubMed ID: 30597087 [TBL] [Abstract][Full Text] [Related]
11. Genomic insights into Cushing syndrome. Assié G Ann Endocrinol (Paris); 2018 Jun; 79(3):119-122. PubMed ID: 29735160 [TBL] [Abstract][Full Text] [Related]
12. Limited brain diffusion of the glucocorticoid receptor agonist RU28362 following i.c.v. administration: implications for i.c.v. drug delivery and glucocorticoid negative feedback in the hypothalamic-pituitary-adrenal axis. Francis AB; Pace TW; Ginsberg AB; Rubin BA; Spencer RL Neuroscience; 2006 Sep; 141(3):1503-15. PubMed ID: 16806720 [TBL] [Abstract][Full Text] [Related]
14. Rapid as well as delayed inhibitory effects of glucocorticoid hormones on pituitary adrenocorticotropic hormone release are mediated by type II glucocorticoid receptors and require newly synthesized messenger ribonucleic acid as well as protein. Dayanithi G; Antoni FA Endocrinology; 1989 Jul; 125(1):308-13. PubMed ID: 2544406 [TBL] [Abstract][Full Text] [Related]